Company-reported five-year data found lower Alzheimer’s progression among Leqembi users than external comparison groups, while safety risks and the study design limit conclusions about long-term benefit.
Five Years of Leqembi Tied to 36% Lower Risk of Alzheimer’s Progression Compared With Untreated Research Volunteers
by | Nov 17, 2026 | Uncategorized | 0 comments

Recent Comments